Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Show more

12278 Scripps Summit Drive, San Diego, CA, 92131, United States

https://www.fatetherapeutics.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

174.2M

52 Wk Range

$0.66 - $1.94

Previous Close

$1.46

Open

$1.45

Volume

1,873,258

Day Range

$1.41 - $1.54

Enterprise Value

-1.947M

Cash

215.4M

Avg Qtr Burn

-24.37M

Insider Ownership

1.90%

Institutional Own.

79.13%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
FT819 (CAR-19, TCR-KO) Details Systemic lupus erythematosus	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT819 (CAR-19, TCR-KO) Details B-cell lymphoma, Solid tumor/s, Cancer, Chronic lymphocytic leukemia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT825/ONO-8250 Details Solid tumor/s, Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT576 (iNK hnCD16) + daratumumab Details Cancer, Multiple myeloma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT522 (CAR NK Cell Program) Details B-cell lymphoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT839 (CAR T Cell) Details B-cell Malignancies And Autoimmune Diseases	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT836 (CAR T Cell) Details Multiple Myeloma	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT596 (CAR19, hnCD16, IL-15RF) + R-CHOP Details B-cell lymphoma, B-cell malignancies, Chronic lymphocytic leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT596 (CAR19, hnCD16, IL-15RF) + rituximab Details B-cell lymphoma, B-cell malignancies, Chronic lymphocytic leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT516 (NK cells - engineered CD16 FcR) Details Solid tumor/s, B-cell lymphoma, Diffuse large B cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT500 (PD1/PD-L1) Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ProTmune (CD34+) Details Acute graft-versus host disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT538 (hnCD16 + IL-15RF + CD38KO) Details Multiple myeloma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT516 (NK cells - engineered CD16 FcR) + rituximab Details Solid tumor/s, B-cell lymphoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.